Statins in very elderly adults (debate)

Journal of the American Geriatrics Society

Volumn 62, Issue 5, 2014, Pages 943-945

  Stone, Neil J ^a   Intwala, Sunny ^a   Katz, Dan ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; SIMVASTATIN;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMNESIA; ARTHROPATHY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CARDIOMETABOLIC RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL DECISION MAKING; DIABETES MELLITUS; GERIATRIC PATIENT; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; INJURY; METABOLIC SYNDROME X; MUSCLE WEAKNESS; NOTE; PAIN; PRIMARY PREVENTION; SIDE EFFECT; VASCULAR DISEASE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MEMORY; MENTAL HEALTH; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84900531277     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/jgs.12788_1     Document Type: Note

References (10)

1. Collaboration CTTC. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670-1681.
2. Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013;(1): CD004816.
3. Elwyn G, Frosch D, Thomson R, et al. Shared decision making: A model for clinical practice. J Gen Intern Med 2012; 27: 1361-1367.
4. Afilalo J, Duque G, Steele R, et al. Statins for secondary prevention in elderly patients: A hierarchical Bayesian meta-analysis. J Am Coll Cardiol 2008; 51: 37-45.
5. Deedwania P, Stone PH, Bairey Merz CN, et al. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: Results of the Study Assessing Goals in the Elderly (SAGE). Circulation 2007; 115: 700-707.
6. Ridker PM, Pradhan A, MacFadyen JG, et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: An analysis from the Jupiter trial. Lancet 2012; 380: 565-571.
7. Mansi I, Frei CR, Pugh MJ, et al. Statins and musculoskeletal conditions, arthropathies, and injuries. JAMA Intern Med 2013; 173: 1318-1326.
8. FDA Drug Safety Communication: Important Safety Label Changes to Cholesterol-Lowering Statin Drugs [on-line]. Available at http://www.fda.gov/ drugs/drugsafety/ucm293101.htm Accessed August 25, 2013.
9. Zhang H, Plutzky J, Turchin A,. Discontinuation of statins in routine care settings. Ann Intern Med 2013; 159: 75-76.
10. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013. doi: 10.1016/j.jacc.2013.11.002